Phaseline

Companies › Rise Therapeutics

Rise Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Immunology, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
R-2487
Probiotic
–Phase 1Arthritis, RheumatoidNov 2026
R-5780
Probiotic (live microorganism)
–Phase 1Solid Tumor, AdultMar 2029
R-3750
Probiotic
–Phase 1Ulcerative Colitis Chronic Mild–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05666960R-3750Phase 1Ulcerative Colitis Chronic MildImmunologyJul 2026
NCT05961592R-2487Phase 1Arthritis, RheumatoidImmunologyNov 2026
NCT06398418R-5780Phase 1Solid Tumor, AdultOncologyMar 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.